Seeking Alpha
21 Oct 2026, 06:46 UTC · 1h ago
Harmony Biosciences: A Cash Machine With A Patent Ruling Hanging Over It
Impact · against what's priced in
The article provides no catalyst for HRMY as it reinforces the existing market tension between strong cash flow and binary patent risk. The valuation remains tied to the outcome of the AET litigation, a risk the current price already accounts for through its conservative revenue growth expectations.
- HRMY+0.00
Already priced in
- The price assumes
The current revenue base of $0.87 billion and its 40.1% free-cash-flow margin
The article's description of HRMY as a 'cash machine' with 'strong cash generation' simply confirms the robust FCF margins and revenue base that the market already prices in.
What HRMY's price assumes · Sep 14
Top 1 mover · tap to explore
